GT Biopharma Inc (GTBP)

[Rapture2020]

OXIS has the drug compound candidates, MCIT has the molecule delivery vehicle, and that research agreement hints at another entity being involved in the developed results...I agree, who we missing?

---

Here are my guesses:

1. Employees of a regulatory agency (US or EU);

2. A big pharma manufacturer specializing in ADC (Anti-body Drug Conjugates) production. After all, somebody will need to make sufficient quantities of the secret sauce to bring to market. Presently, neither OXIS or MCIT have that capability (to my knowledge);

3. Perhaps a 'strategic partner' Cataldo mentioned in his 2-25 letter to shareholders; or

4. #2 & #3 one in the same?

In my opinion, it looks as if all the ducks have been lined up.

Now, of course, comes the $64,000 question...will the drug(s) show enough promise to advance to clinical trials?

I have to believe the answer to that question will come at some point in 2015.

Good luck all.